In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Opinion|Videos|December 9, 2024
Integration of Cardiovascular Care Into CKD Management
Key Takeaways
- Cardiovascular risk management is essential in CKD treatment due to the high prevalence of cardiovascular complications in this population.
- Addressing traditional and CKD-specific risk factors is vital for effective cardiovascular risk management.
Panelists discuss the role of cardiovascular risk management for patients with chronic kidney disease (CKD) and how cardiovascular care can be effectively integrated into CKD management strategies.
Advertisement
- What role should cardiovascular risk management play in the treatment for these patients?
- How can cardiovascular care be integrated into CKD management?
Advertisement
Related to this article
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Advertisement
Advertisement
Trending on HCPLive
1
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD
2
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
3
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
4
AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD
5